Corrigendum to: Serum peptides as candidate biomarkers for dementia with Lewy bodies (Int J Geriatr Psychiatry, 30, (1195-1206), 10.1002/gps.4274);Serum peptides as candidate biomarkers for dementia with Lewy bodies

International Journal of Geriatric Psychiatry

Volumn 30, Issue 12, 2015, Pages 1195-1206

  Suzuki, Itsuku ^a   Noguchi, Miwa ^a   Arito, Mitsumi ^b   Sato, Toshiyuki ^b   Omoteyama, Kazuki ^b   Maedomari, Mioto ^a   Hasegawa, Hiroshi ^a   Suematsu, Naoya ^b   Okamoto, Kazuki ^b   Kato, Tomohiro ^b   Yamaguchi, Noboru ^a   Kurokawa, Manae S ^b  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b ST MARIANNA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

biomarkers; dementia with Lewy bodies; mass spectrometry; serum peptides

Indexed keywords

BIOLOGICAL MARKER; COMPLEMENT COMPONENT C4B; FIBRINOGEN; FIBRINOGEN ALPHA; LIPOPOLYSACCHARIDE BINDING PROTEIN; UNCLASSIFIED DRUG; WNT 2B PROTEIN; WNT2 PROTEIN; PEPTIDE; PEPTIDE FRAGMENT;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CONTROLLED STUDY; DIFFUSE LEWY BODY DISEASE; DISEASE CLASSIFICATION; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; VALIDATION PROCESS; BLOOD; CASE CONTROL STUDY; MASS SPECTROMETRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROCEDURES; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; BIOMARKERS; CASE-CONTROL STUDIES; FEMALE; HUMANS; LEWY BODY DISEASE; MALE; MASS SPECTROMETRY; MIDDLE AGED; MULTIVARIATE ANALYSIS; PEPTIDE FRAGMENTS; PEPTIDES; SENSITIVITY AND SPECIFICITY;

EID: 84947018033     PISSN: 08856230     EISSN: 10991166     Source Type: Journal    
DOI: 10.1002/gps.4420     Document Type: Erratum

References (29)

1. Abdi F, Quinn JF, Jankovic J, et al., 2006. Detection of biomarkers with a multiplex quantitative proteomic platform in cerebrospinal fluid of patients with neurodegenerative disorders. J Alzheimers Dis 9: 293-348.
2. American Psychiatric Association. 1994. Diagnostic and Statistical Manual of Mental Disorders. 4th edn. Washington: American Psychiatric Association.
3. Bibl M, Mollenhauer B, Esselmann H, et al., 2006. CSF amyloid-beta-peptides in Alzheimer's disease, dementia with Lewy bodies and Parkinson's disease dementia. Brain 129: 1177-1187.
4. Clark CM, Xie S, Chittams J, et al., 2003. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses? Arch Neurol 60: 1696-1702.
5. Cortes-Canteli M, Paul J, Norris EH, et al., 2010. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease. Neuron 66: 695-709. DOI: 10.1016/j.neuron.2010.05.014.
6. de Jong D, Jansen RW, Pijnenburg YA, et al., 2007. CSF neurofilament proteins in the differential diagnosis of dementia. J Neurol Neurosurg Psychiatry 78: 936-938.
7. Ferman TJ, Smith GE, Kantarci K, et al., 2013. Nonamnestic mild cognitive impairment progresses to dementia with Lewy bodies. Neurology 81: 2032-2038. DOI: 10.1212/01.wnl.0000436942.55281.47.
8. Forsyth CB, Shannon KM, Kordower JH, et al., 2011. Increased intestinal permeability correlates with sigmoid mucosa alpha-synuclein staining and endotoxin exposure markers in early Parkinson's disease. PLoS One 6: e28032. DOI: 10.1371/journal.pone.0028032.
9. Hatsugai M, Kurokawa MS, Kouro T, et al., 2010. Protein profiles of peripheral blood mononuclear cells are useful for differential diagnosis of ulcerative colitis and Crohn's disease. J Gastroenterol 45: 488-500. DOI: 10.1007/s00535-009-0183-y.
10. Herbert MK, Aerts MB, Kuiperij HB, et al., 2014. Addition of MHPG to Alzheimer's disease biomarkers improves differentiation of dementia with Lewy bodies from Alzheimer's disease but not other dementias. Alzheimers Dement 10: 448-455. DOI: 10.1016/j.jalz.2013.05.1775.
11. Iseki E, Marui W, Akiyama H, Uéda K, Kosaka K,. 2000. Degeneration process of Lewy bodies in the brains of patients with dementia with Lewy bodies using alpha-synuclein-immunohistochemistry. Neurosci Lett 286: 69-73.
12. Jerala R,. 2007. Structural biology of the LPS recognition. Int J Med Microbiol 297: 353-363.
13. Katoh M,. 2005. WNT2B: comparative integromics and clinical applications (Review). Int J Mol Med 16: 1103-1108.
14. McKeith IG, Dickson DW, Lowe J, et al., Consortium on DLB. 2005. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology 65: 1863-1872.
15. McKeith I, Mintzer J, Aarsland D, et al., International Psychogeriatric Association Expert Meeting on DLB. 2004. Dementia with Lewy bodies. Lancet Neurol 3: 19-28.
16. McKhann G, Drachman D, Folstein M, et al., 1984. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944.
17. Mollenhauer B, Cepek L, Bibl M, et al., 2005. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies. Dement Geriatr Cogn Disord 19: 164-170.
18. Mollenhauer B, Cullen V, Kahn I, et al., 2008. Direct quantification of CSF alpha-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Exp Neurol 213: 315-325. DOI: 10.1016/j.expneurol.2008.06.004.
19. Mollenhauer B, Steinacker P, Bahn E, et al., 2007. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies. Neurodegener Dis 4: 366-375.
20. Noguchi M, Sato T, Nagai K, et al., 2014. Roles of serum fibrinogen α chain-derived peptides in Alzheimer's disease. Int J Geriatr Psychiatry 29: 808-818. DOI: 10.1002/gps.4047.
21. Ohrfelt A, Grognet P, Andreasen N, et al., 2009. Cerebrospinal fluid alpha-synuclein in neurodegenerative disorders-a marker of synapse loss? Neurosci Lett 450: 332-335. DOI: 10.1016/j.neulet.2008.11.015.
22. Parnetti L, Tiraboschi P, Lanari A, et al., 2008. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies. Biol Psychiatry 64: 850-855. DOI: 10.1016/j.biopsych.2008.02.016.
23. Petersen RC, Smith GE, Waring SC, et al., 1999. Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56: 303-308.
24. Steinacker P, Mollenhauer B, Bibl M, et al., 2004. Heart fatty acid binding protein as a potential diagnostic marker for neurodegenerative diseases. Neurosci Lett 370: 36-39.
25. Togo T, Iseki E, Marui W, et al., 2001. Glial involvement in the degeneration process of Lewy body-bearing neurons and the degradation process of Lewy bodies in brains of dementia with Lewy bodies. J Neurol Sci 184: 71-75.
26. Wada-Isoe K, Imamura K, Kitamaya M, Kowa H, Nakashima K,. 2008. Serum heart-fatty acid binding protein levels in patients with Lewy body disease. J Neurol Sci 266: 20-24.
27. Wada-Isoe K, Michio K, Imamura K, et al., 2007. Serum proteomic profiling of dementia with Lewy bodies: diagnostic potential of SELDI-TOF MS analysis. J Neural Transm 114: 1579-1583.
28. Waragai M, Nakai M, Wei J, et al., 2007. Plasma levels of DJ-1 as a possible marker for progression of sporadic Parkinson's disease. Neurosci Lett 425: 18-22.
29. Zhang Y, Mei P, Lou R, et al., 2002. Gene expression profiling in developing human hippocampus. J Neurosci Res 70: 200-208.